Abstracts tagged "SLE and depression"

Abstract Number: 30 • 2017 Pediatric Rheumatology Symposium
Cross-sectional Analysis of Depression and Medication Non-Adherence in Childhood-onset Systemic Lupus Erythematosus
Alaina M. Davis¹, T. Brent Graham¹, Yuwei Zhu² and Melissa L. McPheeters³, ¹Pediatric Rheumatology, Monroe Carell Junior Children's Hospital at Vanderbilt, Division of Pediatric Rheumatology, Nashville, TN, ²Biostatistics, Vanderbilt University, Department of Biostatistics, Nashville, TN, ³Health Policy, Vanderbilt University Medical Center, Department of Health Policy, Nashville, TN
Background/Purpose: The objectives of this study were to estimate prevalence of depression and medication non-adherence, describe demographic and disease characteristics associated with depression and medication…
Abstract Number: 1766 • 2016 ACR/ARHP Annual Meeting
Impact of Depression on SLE Flares
Shikha Rathi¹, Alexis Zavitsanos², King Soon Goh¹, Roberto Caricchio¹ and Lauren Freid¹, ¹Temple University Hospital, Philadelphia, PA, ²Rheumatology, Temple University Hospital, Philadelphia, PA
Background/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE) involves a wide range of peripheral and central neuropsychiatric manifestations. Depression is one of those and is very common…
Abstract Number: 1967 • 2016 ACR/ARHP Annual Meeting
Depression Is a Risk Factor for Low Treatment Adherence in African American People with Systemic Lupus Erythematosus
Cristina Drenkard¹, Sonia Mathew², Gaobin Bao³ and S. Sam Lim³, ¹Emory University School of Medicine, Atlanta, GA, ²Mercer School of Medicine, Macon, GA, ³Medicine, Emory University School of Medicine, Atlanta, GA
Background/Purpose: African American (AA) people with Systemic Lupus Erythematosus (SLE) are at high risk for severe disease and depression, and often require complex medication regimes.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].